Gocovri Now Available to Treat Dyskinesia in Parkinson's Disease Patients

Gocovri is available as extended-release capsules for oral administration
Gocovri is available as extended-release capsules for oral administration

[Updated 6/28/18]

Adamas announced the availability of Gocovri (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. 

Gocovri was approved by the Food and Drug Administration (FDA) in August 2017 as the first drug for this indication. Gocovri is a weak, uncompetitive antagonist of the NMDA receptor. It is thought to work by decreasing the intensity and duration of motor complications by selectively inhibiting overactive NMDA-glutamate receptors. 

Related Articles

If needed, Gocovri capsules may be administered by opening and sprinkling the entire contents on a teaspoonful of soft food (eg, applesauce). Treatment with Gocovri is contraindicated in patients with end stage renal disease (creatinine clearance <15mL/min/1.73m2). 

Gocovri is available as 68.5mg and 137mg strength extended-release capsules in 60-count bottles.

For more information call (844) 462-6874 or visit Gocovri.com.